Fig 5. Antitumor effect of 4AZA2891 in a HT-29 xenograft model.

(A) The efficacy of 4AZA2891 was evaluated in a xenograft model. 10⁷ HT-29 cells were injected subcutaneously in the flank of male nude mice. After tumor development, the mice were assigned to different treatment groups: vehicle, 4AZA2891 at 15 mg/kg/d administered 5 days a week for 2 weeks or 30 mg/kg/d every other day for 2 weeks. Treatments were given by IV administration. (B) Body weight evolution of mice for each treatment group. (C) Ratio treated over control relative tumor volume (T/C). (D) Tumor volume at the end of the treatment period. (The grey zones represent the treatment period; the arrowheads indicate the schedule of treatment administration).